Is Valeant Pharmaceuticals Intl Inc. Worth the Risk?

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has had a devastating past few months, and while the chain of bad news may be at an end, the stock is still a risky investment.

The Motley Fool

There are few things that have gone right for Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) over the past few months. Just a short six months ago the company was the best-performing stock on the market with one of the largest market caps.

There’s a lot that has changed within and related to Valeant in the past few months. Here’s a review of what has changed and how it impacts investors.

Valeant’s stock has dropped faster than the market has

Over the course of the past six months the stock has dropped nearly 65%. While stocks rise and fall on a daily basis, Valeant’s peak made it the largest company on the TSX by market cap, which makes the collapse of the stock that much more significant to investors.

One of the many quotes by Warren Buffett that is often repeated is “be fearful when others are greedy, and greedy when others are fearful.” This quote couldn’t be further from the truth for Valeant, and investors wondering if they should invest in the company should ask themselves whether they are fearful or greedy.

So in other words, at the current price Valeant can be purchased at a bargain, but is the investment worth the risk? There are those that see the company as a large risk, and then there are those that see this as an opportunity to double down and purchase more shares.

Valeant’s business model has drawn a lot of attention

Valeant is well known as a company that grows primarily through acquisitions. More than 100 companies have been acquired by Valeant over the past seven years. What happens once Valeant acquires those companies is what has been the subject of much debate and attention lately.

The company has come under fire in recent months over unfair pricing of drugs from newly acquired companies, even drawing the ire of candidates of the 2016 presidential election. That type of attention has driven the stock price down and even prompted presidential candidate Hillary Clinton to make a call for prescription-drug-pricing reform as part of her election campaign.

Whether or not that reform will actually occur remains a question that won’t be answered until after the election at the earliest and more than likely several years down the road. The more pressing question for both investors and Valeant is if the current model of growth via acquisition then selling medication at higher price points is still sustainable.

When companies go through hard times, investors and employees will turn to leadership for guidance. Unfortunately for Valeant, this is another source of concern as CEO Michael Pearson has been forced into medical leave after being struck ill with a bad case of pneumonia.

Valeant as a company is a great investment. The business model has worked well for the company, and given the amount of bad news the company has had over the past six months, it is arguable that the stock has suffered enough on that bad news.

Fool contributor Demetris Afxentiou has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

oil pumps at sunset
Energy Stocks

How a $25,000 TFSA Could Fund Your Retirement

Canadians can turn to the TFSA to help provide a meaningful income stream in retirement.

Read more »

Canada day banner background design of flag
Investing

3 of the Best Canadian Stocks to Buy Right Now

These three Canadian stocks are ideal for balancing wealth-creation opportunities with stability and income generation in this uncertain outlook.

Read more »

Blocks conceptualizing Canada's Tax Free Savings Account
Dividend Stocks

TFSA Strategy: How to Earn $500 a Month in Tax-Free Dividend Income

Canadians can earn $500 in tax-free dividend income or another desired amount every month using a simple TFSA strategy.

Read more »

coins jump into piggy bank
Energy Stocks

Canadian Natural Resources vs. Enbridge: The Better Dividend Stock to Buy Today

Both CNQ and ENB have impressive payout records, consistently paying and increasing their dividends for decades.

Read more »

doctor uses telehealth
Dividend Stocks

TFSA Investors: This Monthly Dividend Stock Yields 7.6%

This REIT offers investors a monthly yield investors and a regular and frequent passive income stream to supplement their regular…

Read more »

shopper chooses vegetables at grocery store
Dividend Stocks

Loblaw vs. Empire: Which Grocery Stock Would I Choose for Long-Term Growth?

Both grocers benefit from repeat shoppers. I’d give Loblaw the edge for the ways it can earn more from those…

Read more »

Retirees sip their morning coffee outside.
Dividend Stocks

2 Canadian Stocks to Buy and Hold for 20 More Years

CP Rail (TSX:CP) and another outstanding Canadian stock that's more than worth holding for many decades.

Read more »

ETF is short for exchange traded fund, a popular investment choice for Canadians
Dividend Stocks

2 Top TSX ETFs to Buy and Hold in a TFSA Forever

Looking for top TSX ETFs for your TFSA? Explore how VFV and VDY combine U.S. stock exposure and Canadian dividends…

Read more »